David Elkins Biography and Net Worth

David Elkins is the executive vice president and chief financial officer responsible for Global Business Operations, which includes Business Insights and Analytics, Global Finance and Global Procurement. David also currently serves as the executive sponsor of the company’s PRIDE Alliance People and Business Resource Group.

“Our team creates incredible partnerships across the business to secure and build value for the company and our patients. Our team also plays a vital part in promoting health — our financial health,” says David. “It is our role to ensure we strategically and efficiently invest and deploy our resources in a manner that maximizes value for our patients and all our other stakeholders as we advance the need for innovative medicines.”

David joined Celgene in July 2018 after several years at Johnson & Johnson (J&J), where he served as chief financial officer for that company’s Consumer Products, Medical Devices and Corporate Functions. Prior to J&J, his experiences include EVP & chief financial officer of Becton, Dickinson and Company, a public global medical technology company. From 1995 to 2008, he held roles of increasing responsibility at AstraZeneca, and he began his career in finance at the Boeing Company in 1991.

David earned his bachelor’s degree from the University of Delaware, an MS from the University of Pennsylvania, and an MBA from Drexel University.

What is David V. Elkins' net worth?: The estimated net worth of David V. Elkins is at least $5.46 million as of September 13th, 2022. Mr. Elkins owns 100,460 shares of Bristol-Myers Squibb stock worth more than $5,458,996 as of November 2nd. This net worth approximation does not reflect any other assets that Mr. Elkins may own. Additionally, Mr. Elkins receives an annual salary of $2,280,000.00 as CFO at Bristol-Myers Squibb. Learn More about David V. Elkins' net worth.
How old is David V. Elkins?: Mr. Elkins is currently 56 years old. There are 7 older executives and no younger executives at Bristol-Myers Squibb. The oldest executive at Bristol-Myers Squibb is Dr. Joseph J. Eiden Jr., Head of Medical Affairs, who is 75 years old. Learn More on David V. Elkins' age.
What is David V. Elkins' salary?: As the CFO of Bristol-Myers Squibb, Mr. Elkins earns $2,280,000.00 per year. There are 3 executives that earn more than Mr. Elkins. The highest earning executive at Bristol-Myers Squibb is Dr. Christopher S. Boerner Ph.D., CEO & Chairman, who commands a salary of $3,140,000.00 per year. Learn More on David V. Elkins' salary.
How do I contact David V. Elkins?: The corporate mailing address for Mr. Elkins and other Bristol-Myers Squibb executives is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. Bristol-Myers Squibb can also be reached via phone at (212) 546-4000 and via email at [email protected]. Learn More on David V. Elkins' contact information.
Has David V. Elkins been buying or selling shares of Bristol-Myers Squibb?: David V. Elkins has not been actively trading shares of Bristol-Myers Squibb during the past quarter. Most recently, David V. Elkins sold 133,951 shares of the business's stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $71.30, for a transaction totalling $9,550,706.30. Following the completion of the sale, the chief financial officer now directly owns 100,460 shares of the company's stock, valued at $7,162,798. Learn More on David V. Elkins' trading history.
Who are Bristol-Myers Squibb's active insiders?: Bristol-Myers Squibb's insider roster includes Mark Alles (CEO), Christopher Boerner (EVP), Giovanni Caforio (CEO), Adam Dubow (SVP), Joseph Eid (SVP), John Elicker (EVP), David Elkins (CFO), Sandra Leung (EVP), Dinesh Paliwal (Director), Robert Plenge (EVP), Ann Powell (EVP), Theodore Samuels, II (Director), Karen Santiago (SVP), Louis Schmukler (EVP), Rupert Vessey (EVP), and Paul von Autenried (EVP). Learn More on Bristol-Myers Squibb's active insiders.
Are insiders buying or selling shares of Bristol-Myers Squibb?: During the last year, Bristol-Myers Squibb insiders bought shares 3 times. They purchased a total of 13,571 shares worth more than $672,994.06. The most recent insider tranaction occured on December, 5th when CEO Christopher S Boerner bought 2,000 shares worth more than $99,560.00. Insiders at Bristol-Myers Squibb own 0.1% of the company. Learn More about insider trades at Bristol-Myers Squibb.
Information on this page was last updated on 12/5/2023.

David V. Elkins Insider Trading History at Bristol-Myers Squibb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/13/2022	Sell	133,951	$71.30	$9,550,706.30	100,460
8/12/2021	Sell	99,691	$66.95	$6,674,312.45

David V. Elkins Buying and Selling Activity at Bristol-Myers Squibb

Bristol-Myers Squibb Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $54.32

$54.20

$55.90

50 Day Range

MA: $51.26

$48.12

$55.74

2 Week Range

Now: $54.32

$39.35

$56.20

Volume

12,894,832 shs

Average Volume

14,484,395 shs

Market Capitalization

$110.13 billion

P/E Ratio

N/A

Dividend Yield

4.56%

Beta

0.46

From Porter & Company | Ad

The AI boom is just getting started. And the real wealth has still to be made…

You must read this new presentation from Porter Stansberry.

David Elkins Biography and Net Worth

What is David V. Elkins' net worth?

How old is David V. Elkins?

What is David V. Elkins' salary?

How do I contact David V. Elkins?

Has David V. Elkins been buying or selling shares of Bristol-Myers Squibb?

Who are Bristol-Myers Squibb's active insiders?

Are insiders buying or selling shares of Bristol-Myers Squibb?